In side-by-side comparisons, cetuximab-IONPs were more effective than cetuximab alone and offered significantly increased tumor cell toxicity in vitro against human GBM neurospheres, GSCs, and GBM CD133-negative cells expressing various levels of wtEGFR. This evidence concerns the gene PROM1 and neoplasm.